Sildenafil and avanafil are separate active ingredients within the phosphodiesterase type 5 (PDE5) inhibitor class. Both enhance nitric-oxide-related cGMP signaling by inhibiting PDE5, but sharing a drug class does not make their pharmacokinetic or product profiles identical. The clearest differences appear in peak-concentration timing, labeled administration timing, food effects, selectivity and metabolism.
Under fasting conditions, sildenafil reaches maximum observed plasma concentrations within approximately 30 to 120 minutes, with a median Tmax of about 60 minutes. Avanafil is more rapidly absorbed in its labeled pharmacokinetic studies, with a median fasting Tmax of approximately 30 to 45 minutes. These values describe plasma concentration timing and should not be treated as direct measurements of when an individual clinical response begins.
This page compares sildenafil and avanafil neutrally rather than identifying a universal preferred medicine. Stendra is treated here as the brand context for avanafil, not as a third active ingredient. For the wider drug-class framework, see sildenafil vs other PDE5 inhibitors.
Sildenafil and avanafil share a primary pharmacological target but remain different molecules. Both inhibit PDE5 and are used in erectile-dysfunction product contexts, yet each has its own concentration-time profile, metabolic characteristics and regulatory labeling.
A useful comparison therefore separates class-level similarities from drug-specific properties. The fact that avanafil reaches peak plasma concentration sooner on average does not by itself establish a proportionally faster clinical response, just as similar elimination half-lives do not mean the drugs have identical response windows.
The table below provides the high-level framework before the individual differences are examined in more detail.
| Feature | Sildenafil | Avanafil |
|---|---|---|
| Drug class | PDE5 inhibitor | PDE5 inhibitor |
| Active ingredient | Sildenafil | Avanafil |
| Primary target | PDE5 | PDE5 |
| Fasting Tmax | 30–120 minutes; median about 60 minutes | Median about 30–45 minutes |
| Terminal elimination half-life | About 4 hours | About 5 hours |
| U.S. ED product form | Oral tablets | Oral tablets |
| Same molecule? | No | No |
Sildenafil and avanafil work through the same broad pharmacological mechanism. During sexual stimulation, local nitric oxide signaling increases cGMP in the corpus cavernosum; PDE5 normally contributes to cGMP breakdown. Inhibiting PDE5 allows cGMP signaling to persist longer and supports smooth-muscle relaxation and blood inflow.
Neither medicine acts simply by creating an erection independently of physiological signaling. PDE5 inhibition amplifies the existing NO-cGMP pathway, which is why mechanism should be distinguished from a direct smooth-muscle relaxant mechanism.
The sildenafil-specific pathway is covered in greater depth on sildenafil PDE5 inhibition and sildenafil and the NO-cGMP pathway.
| Mechanistic Feature | Sildenafil | Avanafil |
|---|---|---|
| PDE5 inhibition | Yes | Yes |
| NO-cGMP pathway relevance | Yes | Yes |
| Sexual stimulation remains relevant | Yes | Yes |
| Identical molecular structure | No | No |
Although both drugs inhibit PDE5, their in-vitro selectivity profiles across the wider phosphodiesterase family are not identical. Sildenafil is approximately 10-fold more potent against PDE5 than PDE6 in published product labeling, while avanafil is described as more than 100-fold more potent against PDE5 than PDE6.
PDE6 is particularly relevant to pharmacological discussion because it participates in retinal phototransduction. The different selectivity ratios demonstrate that two medicines in the same PDE5 inhibitor class can interact differently with related phosphodiesterases.
Selectivity is a molecular property rather than a direct measure of overall treatment quality. A larger in-vitro selectivity ratio should not be converted by itself into a conclusion about individual efficacy, tolerability or preferred treatment.
| Selectivity Concept | Sildenafil | Avanafil |
|---|---|---|
| Primary intended PDE target | PDE5 | PDE5 |
| PDE5 vs PDE6 selectivity in vitro | Approximately 10-fold | Greater than 100-fold |
| Identical phosphodiesterase selectivity profile? | No | No |
| Selectivity alone establishes clinical superiority? | No | No |
Both medicines are absorbed after oral administration and then undergo distribution, metabolism and elimination, but their concentration-time curves are drug-specific. One of the clearest measurable differences is the location of the concentration peak: sildenafil has a fasting Tmax range of approximately 30 to 120 minutes with a median near 60 minutes, whereas avanafil has a reported median fasting Tmax of approximately 30 to 45 minutes.
Tmax answers only when the maximum observed plasma concentration occurs. It does not tell us the magnitude of that peak, total systemic exposure or the exact time at which a clinical response begins. Cmax, AUC and pharmacodynamic observations answer different questions.
For the terminology and interpretation of these measurements on the sildenafil side, see sildenafil pharmacokinetics and the sildenafil concentration-time curve.
| PK Dimension | Sildenafil | Avanafil |
|---|---|---|
| Administration | Oral | Oral |
| Fasting Tmax | 30–120 minutes; median approximately 60 minutes | Median approximately 30–45 minutes |
| Terminal half-life | Approximately 4 hours | Approximately 5 hours |
| Primary metabolic context | Predominantly hepatic CYP3A metabolism | Predominantly hepatic CYP3A4 metabolism |
| Same concentration-time profile? | No | No |
The shorter median Tmax reported for avanafil is an important pharmacokinetic difference, but Tmax should not be used as a synonym for onset. Tmax identifies the sampling time associated with maximum observed plasma concentration, whereas clinical onset concerns when a meaningful pharmacodynamic response can first be observed.
A PDE5 inhibitor can begin producing pharmacological effects before Cmax is reached. Conversely, reaching the plasma concentration peak does not guarantee that every individual will experience the same response at that moment. The concentration-effect relationship also depends on physiological signaling and individual variability.
This distinction is particularly important on a comparison page because otherwise a PK number can easily be mistaken for a treatment-timing claim. For the sildenafil-specific distinction, see sildenafil Tmax and sildenafil onset.
| Metric | Domain | What It Means |
|---|---|---|
| Tmax | Pharmacokinetics | Time of the maximum observed plasma concentration |
| Cmax | Pharmacokinetics | Magnitude of the maximum observed plasma concentration |
| Onset | Pharmacodynamics / clinical timing | Beginning of an observable effect |
The U.S. product labels also use different pre-activity timing language. Sildenafil tablet labeling generally centers administration around approximately one hour before sexual activity, while allowing a broader labeled window extending from about 30 minutes to four hours before activity.
Stendra labeling for avanafil includes administration as early as approximately 15 minutes before sexual activity in some labeled dosing contexts, while another labeled dosing context uses approximately 30 minutes. These statements describe product administration instructions from clinical-development and labeling frameworks; they are not guaranteed individual onset times.
This distinction makes the avanafil-versus-sildenafil timing comparison more informative than simply comparing Tmax values. Pharmacokinetic peak timing, labeled administration timing and individual clinical response are related concepts, but they are not interchangeable measurements.
| Timing Context | Sildenafil | Avanafil |
|---|---|---|
| General U.S. label timing context | Typically approximately 1 hour before sexual activity | Can be as early as approximately 15 minutes in specified labeled contexts |
| Does label timing equal Tmax? | No | No |
| Does label timing guarantee individual onset? | No | No |
| Sexual stimulation relevant to response? | Yes | Yes |
A high-fat meal slows the absorption rate of both medicines in pharmacokinetic studies, but the measured changes are drug-specific. For sildenafil tablets, a high-fat meal produces a mean Tmax delay of approximately 60 minutes and a mean Cmax reduction of about 29 percent.
For avanafil, the labeled high-fat-meal study reports a mean Tmax delay of approximately 1.12 to 1.25 hours and a mean Cmax reduction of about 39 percent. AUC decreased by only about 3.8 percent in that study, and the avanafil label characterizes the resulting Cmax and AUC changes as having minimal clinical significance.
These data illustrate why food effects should be compared parameter by parameter rather than summarized simply as 'food affects one more than the other.' Sildenafil-specific interpretation is covered on the sildenafil food effects page.
| High-Fat Meal Finding | Sildenafil | Avanafil |
|---|---|---|
| Mean Tmax delay | Approximately 60 minutes | Approximately 1.12–1.25 hours |
| Mean Cmax change | Approximately 29% lower | Approximately 39% lower |
| AUC finding highlighted in label | Food effect is primarily described through slower absorption and lower Cmax | Approximately 3.8% lower |
| Food changes absorption timing? | Yes | Yes |
Sildenafil and avanafil do not have dramatically different terminal elimination half-lives in their current labels. Sildenafil and its major circulating metabolite have terminal half-lives of approximately four hours, while avanafil has a terminal elimination half-life of approximately five hours.
That numerical similarity does not mean their clinical timing profiles must be identical. Half-life describes the decline of circulating drug concentration, while duration of effect is a pharmacodynamic concept influenced by concentration, target engagement, physiology and the conditions under which response is assessed.
For sildenafil, this distinction is treated separately on sildenafil half-life and sildenafil duration.
| Concept | Sildenafil | Avanafil |
|---|---|---|
| Terminal elimination half-life | About 4 hours | About 5 hours |
| Half-life equals clinical duration? | No | No |
| Duration determined by PK alone? | No | No |
Both sildenafil and avanafil rely substantially on hepatic CYP3A metabolism, so CYP3A-modifying medicines can be important to their exposure and interaction context. Sildenafil is cleared predominantly through CYP3A, with CYP2C9 serving as a minor pathway. Avanafil is metabolized mainly through CYP3A4, with a CYP2C pathway contributing to a lesser extent.
Both medicines also form metabolites, but the metabolites are not identical and do not contribute in the same way. Sildenafil's major circulating N-desmethyl metabolite retains pharmacological activity, while avanafil produces major circulating metabolites including M4 and M16, with M4 retaining limited PDE5 activity and M16 being inactive against PDE5.
Shared CYP3A involvement therefore does not mean the medicines have identical metabolic disposition or interaction magnitude. The sildenafil-specific pathway is covered on sildenafil metabolism and sildenafil and CYP3A4.
| Metabolic Feature | Sildenafil | Avanafil |
|---|---|---|
| Major pathway | CYP3A | CYP3A4 |
| Minor CYP contribution | CYP2C9 | CYP2C pathway |
| Active metabolite present? | Yes | Yes; M4 retains limited PDE5 activity |
| Identical metabolic profile? | No | No |
Because both drugs are administered orally and reach systemic circulation, the same pharmacokinetic vocabulary can be used to describe their profiles. Cmax represents the highest observed plasma concentration, AUC represents integrated systemic exposure and Tmax identifies when the observed peak occurs.
The numerical values of those parameters cannot be compared as though a larger Cmax or AUC automatically represents greater clinical effectiveness. Different molecules can require different concentrations to produce their pharmacological effects, and exposure measurements need to be interpreted within each drug's own potency and pharmacodynamic context.
For a deeper explanation of these concepts on the sildenafil side, see sildenafil exposure, sildenafil Cmax and sildenafil AUC.
| PK Metric | What It Answers | What It Does Not Establish by Itself |
|---|---|---|
| Tmax | When does peak concentration occur? | Clinical onset or superiority |
| Cmax | How high is the observed concentration peak? | Overall clinical effectiveness |
| AUC | How much systemic exposure occurs across time? | Which medicine is preferable |
| Half-life | How quickly does concentration decline? | Exact duration of effect |
Avanafil is the active drug name, while Stendra is the U.S. brand name associated with avanafil tablets. The relationship is therefore a drug-versus-brand distinction rather than a difference between two active ingredients. A query comparing sildenafil with Stendra is pharmacologically a comparison of sildenafil with avanafil.
In the U.S. erectile-dysfunction context, both sildenafil and avanafil are available as oral tablet products. Sildenafil additionally has a much broader generic-product landscape and is associated with other brand and indication contexts outside this direct ED comparison.
For the broader distinction between active ingredient and brand identity on the sildenafil side, see sildenafil brand names and generic sildenafil.
| Name | Identity |
|---|---|
| Sildenafil | Active drug |
| Avanafil | Active drug |
| Stendra | Brand product containing avanafil |
| Generic sildenafil | Generic product context for sildenafil |
The shared PDE5 inhibitor mechanism creates some overlapping safety principles, but sildenafil and avanafil still have separate product labels. Both have important class-related considerations involving vasodilation and concomitant medicines, while the details of interaction management, dose adjustment and use in specific populations remain drug-specific.
For example, nitrates and guanylate-cyclase-stimulator therapy are major contraindication contexts within PDE5 inhibitor labeling. CYP3A-modifying drugs are also relevant because both active ingredients depend substantially on CYP3A metabolism, although their individual prescribing instructions are not interchangeable.
This comparison does not reproduce the full safety labels. Sildenafil-specific information is separated into sildenafil contraindications, sildenafil drug interactions, sildenafil and nitrates and sildenafil and riociguat.
| Label Dimension | Comparison Principle |
|---|---|
| Nitrates | Important PDE5-inhibitor contraindication context |
| Guanylate cyclase stimulators | Important contraindication context |
| CYP3A interactions | Relevant to both, but product-specific instructions differ |
| Specific-population guidance | Requires the individual medicine's label |
Population pharmacokinetic measurements summarize groups, not guaranteed outcomes for a particular person. A median Tmax of 30 to 45 minutes for avanafil and approximately 60 minutes for sildenafil does not mean that every individual will reach peak concentration at those exact times or experience a clinical response according to the same schedule.
Gastrointestinal absorption, food conditions, metabolic activity, interacting medicines and physiological sensitivity can all alter exposure or observed response. This variability is another reason to avoid translating one PK parameter into a universal clinical timing rule.
The general sources of sildenafil variability are discussed on the sildenafil PK variability page.
| Source of Variation | Potential Effect |
|---|---|
| Absorption | Can change early concentration-time behavior |
| Food | Can change the rate of absorption |
| Metabolic activity | Can alter systemic exposure |
| Interacting medicines | Can modify metabolism or pharmacodynamic response |
| Individual pharmacodynamic sensitivity | Can alter observed response at a given exposure |
The most informative sildenafil-versus-avanafil comparison is not simply that both inhibit PDE5. Avanafil has an earlier median plasma peak and different labeled pre-activity timing, while sildenafil has its own established timing framework. Their food effects, selectivity profiles and metabolic details also differ despite substantial class-level overlap.
At the same time, some apparent differences should not be overstated. Their terminal half-lives are relatively close in current labeling, both rely heavily on CYP3A metabolism and both require the wider physiological context of PDE5 inhibition rather than acting as independent triggers of an erectile response.
The result is a comparison between related but distinct PDE5 inhibitors rather than a winner-versus-loser ranking. For other within-class comparisons, see sildenafil vs tadalafil, sildenafil vs vardenafil and sildenafil vs other PDE5 inhibitors.
| Comparison Question | Interpretation |
|---|---|
| Do they share a drug class? | Yes. Both are PDE5 inhibitors. |
| Are they the same active drug? | No. |
| Does avanafil reach peak plasma concentration sooner on average? | Its labeled median fasting Tmax is earlier than sildenafil's. |
| Does earlier Tmax automatically equal earlier individual clinical onset? | No. |
| Do their labeled timing frameworks differ? | Yes. |
| Do high-fat meals alter both absorption profiles? | Yes, with drug-specific PK changes. |
| Are their elimination half-lives dramatically different? | No. Current labels report approximately 4 hours for sildenafil and 5 hours for avanafil. |
| Does the comparison establish a universal preferred treatment? | No. |
Both are PDE5 inhibitors used in erectile-dysfunction contexts, but they are different active ingredients with different pharmacokinetic, selectivity, food-effect and labeled timing profiles.
Stendra is a brand product containing avanafil. Avanafil is the active drug name, so sildenafil-versus-Stendra is pharmacologically a sildenafil-versus-avanafil comparison.
In current U.S. labeling, sildenafil reaches maximum observed plasma concentration within approximately 30 to 120 minutes with a median around 60 minutes when fasting, while avanafil has a median fasting Tmax of approximately 30 to 45 minutes.
No. Tmax measures the timing of peak plasma concentration, not the exact beginning of an individual's clinical response. Pharmacodynamic response can begin before Cmax and varies between individuals.
U.S. sildenafil labeling generally centers administration around approximately one hour before sexual activity and allows a broader 30-minute-to-4-hour window. Avanafil labeling includes administration as early as approximately 15 minutes before sexual activity in certain labeled dosing contexts. These are labeled administration timings rather than guaranteed onset times.
Current labeling reports a terminal half-life of about 4 hours for sildenafil and about 5 hours for avanafil. Half-life should not be treated as the same thing as duration of clinical effect.
Yes. A high-fat meal delays absorption of both, but the measured PK changes differ. Sildenafil labeling reports an average Tmax delay of about 60 minutes and a Cmax reduction of about 29%, while avanafil labeling reports a Tmax delay of about 1.12 to 1.25 hours and a Cmax reduction of about 39%, with only a small change in AUC.
They share the same broad mechanism of PDE5 inhibition and enhancement of NO-cGMP signaling, but they are different molecules with different phosphodiesterase selectivity and pharmacokinetic profiles.
Their in-vitro selectivity profiles differ. Current labeling describes sildenafil as approximately 10-fold more potent for PDE5 than PDE6 and avanafil as more than 100-fold more potent for PDE5 than PDE6. This molecular difference does not by itself establish overall clinical superiority.
Both depend substantially on hepatic CYP3A metabolism, but their complete metabolic profiles differ. Sildenafil also uses CYP2C9 as a minor pathway, while avanafil labeling describes a minor CYP2C pathway and different circulating metabolites.
The pharmacological comparison does not establish a universal preferred medicine. The drugs differ in timing, selectivity, food effects and other product characteristics, while individual suitability depends on clinical circumstances and the applicable prescribing information.